INTRODUCTION
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201 was a phase 3, multicenter, randomized trial of transplantation of bone marrow (BM) versus granulocyte-colony stimulating factor mobilized peripheral-blood stem cells (PBSC) from HLA compatible unrelated donors in patients with hematologic malignancies. There were no significant differences in 2-year survival probabilities [1] . Only 5% of patients who died had infection listed as the primary cause of death. Analysis of pre-specified secondary endpoints showed that the median time to neutrophil engraftment was 5 days shorter for those randomly assigned to receive PBSC. The total incidence of graft failure was 3% in the PBSC group, compared to 9% in the BM group. These significant findings, as well as data from other clinical trials, have led some to choose PBSC as a preferential graft source [2] [3] [4] [5] [6] . However, the 53% incidence of chronic graft-versus host disease at 2 years in the PBSC group was significantly higher when compared to 41% for the BM group, a finding confirmed by other studies [2] [3] [4] [7] [8] [9] [10] . These secondary analyses suggest that it may be important for patients who are immunosuppressed from prior chemotherapy, and have a lower risk of graft rejection, receive BM grafts, while patients with malignant diseases who have never undergone cytotoxic chemotherapy, who may be at increased risk of rejection of a BM graft, undergo transplant with a PBSC graft. In an effort to provide additional data regarding whether BM or PBSC could be used as a preferential graft source for transplantation, we report a detailed analysis of the infectious complications for 2 years following transplantation from the BMT CTN 0201 trial.
METHODS

Protocol Synopsis
BMT CTN Protocol 0201 opened for accrual in March 2004 and closed in September 2009 meeting the target accrual objective of 550 donor-recipient pairs. Randomization was performed 1:1 to either PBSC or BM and stratified by transplant center and disease risk. Details of the treatment schemes have been reported [1] . Key baseline characteristics were similar in the 2 treatment arms. The primary objective was to compare two-year survival probabilities in the two study arms using an intent-to-treat analysis. Secondary objectives included incidences of neutrophil and platelet engraftment, graft failure, acute graft-versushost disease (GVHD), chronic GVHD, time off all immunosuppressive therapy, relapse, adverse events, immune reconstitution, and quality of life. Moderate or more severe infections were reported on an event-driven Case Report Form, excluding those that occurred pre-transplant, and were tabulated for two years following transplantation.
Infection Prophylaxis
Among the 40 participating transplant centers, infection prophylaxis followed local protocols that were based on national guidelines [11] . Patients underwent their transplant procedure in rooms ventilated with high efficiency particulate air filtration systems to prevent acquisition of exogenous mold infections [12] . During periods of neutropenia, broad-spectrum antibacterial agents were administered that included anti-pseudomonal antibacterial agents for febrile neutropenia [13] . During periods of fever, assessment for infection and augmentation of antimicrobial agents included empirical treatment for yeasts and molds for persistent fever [14] . Medication to prevent Pneumocystis infections generally started within one month after transplantation, following engraftment [15] . Acyclovir was used to prevent herpes simplex and varicella infections. Monitoring guidelines were followed to detect and preemptively treat cytomegalovirus (CMV) infection. [16] Diagnostic strategies for individual pathogens, particularly viral and fungal infections, varied between centers based on local laboratory practices.
Data Collection and Audit
Transplant centers prospectively reported infections for study subjects. Infection onset date, organism, body site, clinical severity, and treatment were captured. Classification of infection severity, including a fatal category, were modified from the definitions used in previous studies [17, 18] : A) Life-threatening infections were those complicated by hypotension or any another event considered life-threatening; B) Severe infections often required treatment with intravenous antibiotics or involved other clinical circumstances that were considered severe.
Based on previous studies that had shown the importance of infection data auditing [17] [18] [19] [20] [21] [22] , the 0201 Infection Team contacted each transplant center to audit the infection data reported for local study patients. In 2012, a pilot audit of infectious disease data for 78 subjects at 15 centers involved with this study indicated value for a full data audit for all transplanted subjects. The BMT CTN Infection reporting form and Instructions for the BMT CTN 0201 Infection Data Review are included as supplementary files to this manuscript. To perform both the pilot audit and entire study audit, the Data and Coordinating Center (The EMMES Corporation, Rockville, MD) prepared an infection summary for each study patient listing the date, organism, body site, severity, and comments regarding each infection as prospectively reported. The auditor confirmed database information by reviewing electronically generated medical records of microbiology, virology, imaging, and surgical pathology reports. Study subjects who were not audited for infection data (n=27, 5%) were excluded from these analyses.
Staphylococcus epidermidis bloodstream infections were counted as an episode of infection if they were treated (even when just one positive blood culture led to treatment) because the treatment course then could have affected whether a second blood culture turned positive, altered the flora of the subject, and created the potential for drug toxicity. CMV, human herpes virus-6, and polyomavirus infections were differentiated as viremia or disease using the BMT CTN Infection reporting form which specifies a body site code; a comment box to add detail about an infection was later reviewed by the audit committee (and JHY) during data cleaning; and the specified definitions of infection severity based on body site affected. All Epstein Barr Virus (EBV) "infections" had the comments specifically reviewed to categorize infections as EBV lymphoproliferative disorder, viremia, or report of a serologic antibody status.
The BMT CTN Definitions of Infection Severity clarify that fever of undetermined origin, upper respiratory infections presumed viral, and potential infections where antibiotics were given without infectious etiology identified were not to be reported. If reported, they were removed from the dataset during final data review.
Statistical Analysis
Infectious complications were analyzed by comparison of the two treatment arms (PBSC versus BM) and adjusted by other relevant clinical risk factors. All data on time to infections or other events were calculated from the date of transplantation. Patients were censored at last follow-up, relapse, second transplant, or 2 years after transplant, whichever came first. When a single organism was recovered multiple times, we followed the algorithm for infection recurrence intervals that were specific to each microorganism, as reported previously [17] .
Analysis of infection incidence (by frequency and cumulative incidence) [17] and infection density (number of infections over time for patients with repeated infections) [20] was performed for overall infections, bacterial infections, viral infections and fungal/parasitic infections, over different time periods (Day 0 to Day 100, Day 100 to 6 months, 6 months to 1 year, 1 year to 2 years, and overall within 2 years of transplantation), by treatment arm. Death was considered a competing risk in cumulative incidence analysis. Infection density was computed by infection frequencies over 100 patient days at risk. The number of patients with infections reported was summarized for each infection type and by treatment arm; specific infectious organisms of interest were explored in descriptive and cumulative incidence analyses.
Multivariate regression analyses were performed to test the contribution of the randomized stem cell source (PBSC versus BM) and other relevant covariates to the incidence of infections. Proportional rates/means models were used to model the infection density over time, with a robust variance estimator to account for within subject correlation [23] . All variables were checked for proportionality using time dependent covariates. The effect of acute and chronic GVHD on infection density was obtained using time-dependent covariates. Multivariate analyses were performed to test the impact of various types of infections on overall survival following transplantation. Cox regression models were used to model survival. The treatment arm variable was forced into all models and baseline covariates were selected using forward stepwise algorithm. Various types of infections were treated as time-dependent covariates in the model. SAS version 9.3 (SAS Institute) was used for data manipulation, infection frequency analysis, and multivariate modeling. R version 2.15.1 was used for cumulative incidence analysis.
RESULTS
Study Population and Total Infections
Among 551 patients enrolled at 48 centers between 01/2004 and 10/2009, 526 patients received a transplant. Response rate was 95% for the infection data audit (249 of the BM arm and 250 on the PBSC arm), resulting in a study population for this analysis of 499 audited patients. Table 1 lists the baseline characteristics of the patients by treatment arm. Baseline characteristics were balanced between the arms and no significant differences were noted.
Overall, 384 patients developed infections of moderate or greater severity: 201 on the BM arm and 183 on the PBSC arm. Of 1347 infection episodes (373 severe and 123 lifethreatening and/or fatal), 710 (53%) occurred on the BM arm and 637 (47%) on the PBSC arm ( Figure 1 ). The majority of infection episodes on each treatment arm were of moderate severity ( Figure 1a ). However, when patients were categorized by infection of worst severity, 84 patients on the BM arm had a severe infection as their most clinically serious infection, compared to 68 patients on the PBSC arm ( Figure 1b , p = 0.6). (Figure 3f , P = .81).
Infection Density
The overall infection density for the study was 0.63 events per 100 patient days at risk; 0.67 for BM and 0.60 for PBSC ( Figure 4a ). The infection density of bacterial infections was 0.4 for both arms (Figure 4b ). The infection density for viral infections was 0.2 in both arms ( Figure 4c ). The infection density for fungal/parasitic infections was 0.04 and 0.05 for the BM and the PBSC arm, respectively ( Figure 4d ). Infection density for each assessment period was computed by looking into the infections reported during this period over the risk days during this period. For example, bacterial bloodstream and non-bloodstream infections had their highest density during the Day 0 to Day 100 interval (Figure 4e and 4f), and decreased over time ( Table 3 ). The infection density for infections of moderate, severe, and life-threatening and/or fatal severity followed a similar trend with regard to infection density over time (Figures 4g, 4h , and 4i).
Relationship of Infection to GVHD: Multivariate Analyses
The baseline covariates in Table 1 were considered in the multivariate analyses. In multivariate analyses of infection density, there were no significant differences between PBSC and BM for density of bacterial or fungal infections (Table 4) . For viral infections, a significant interaction was detected between graft type and disease risk (P < 0.001), so that for early disease the risk of viral infections was lower with PBSC compared to BM, while for advanced / late disease, risks of viral infection were higher with PBSC. However, there was no overall significant effect of graft type on viral infections if this interaction was ignored.
Both acute and chronic GVHD were associated with increased rates of bacterial and fungal infections in both the BM and PBSC arms ( Table 5 ). Only acute (but not chronic) GVHD was associated with increased rates of viral infections.
After adjustment for significant covariates including age, conditioning regimen, HLA matching, and disease risk, bacterial and fungal, but not viral or even specifically CMV, infections were associated with worse survival in both BM and PBSC recipient groups (Table 6 ).
Infections within 30 days prior to Death
Infection was reported as a primary cause of death for 11 of 133 deceased patients on the BM arm and for 9 of 139 on the PBSC arm. Patients where infection was a de novo cause of death included 2 viral infections (2/11 = 18% of BM, and 22% of PBSC, or ~ 20%) and 1 fungal infection (9% of BM, and 11% of PBSC, or ~ 10%) on each arm, with the remainder being bacterial infections generally associated with multiorgan failure (73% of BM, and 67% of PBSC, or ~ 70%). We reviewed infections within 30 days of death to examine the proximate relationship of any infections to death. On the BM arm, 111 infections were reported on 50 patients within 30 days prior to death; on the PBSC arm, 96 infections were reported on 39 patients. Of these 207 infections reported within 30 days of death, bacteria accounted for 138, viruses for 38, and fungi/parasites for 30. Patients with acute or chronic GVHD reported as the cause of death, and an infection noted as being the most severe within 30 days of death, had a high percentage of fungal infections (20/52 or ~ 38%), with fewer viral (~ 14%), bacterial (~44%), or protozoal infections (~ 4%).
Relationship of Infection to Engraftment
The cumulative incidence of infections that occurred among engrafted patients, 1 year following engraftment, was 71.1% (95%CI, 64.4-76.9) for the BM arm vs. 67.2% (95%CI, 60.1-73.2) for the PBSC arm (P = .23) ( Figure 5a ). The cumulative incidence of preengraftment infections (occurring before Day 30) was 47.9% (95%CI, 41.5-53.9) for the BM arm vs. 32.8% (95%CI, 27.1-38.7) for the PBSC arm (P = .002) (Figure 5b ).
DISCUSSION
We analyzed all infection events during two years of follow-up for two randomly assigned graft source treatment arms for unrelated donor myeloablative hematopoietic cell transplantation patients who participated in BMT CTN 0201 (a minority were not myeloablative). When the trial was designed, we hypothesized that infection may play a major role in augmenting morbidity and mortality in this randomized trial, so infection events were collected prospectively as a prespecified secondary outcome. This multicenter, randomized phase 3 trial demonstrated that infections remain common and occurred for 85% of BM recipients and 80% of PBSC recipients. Strengths of this prospective study are the large sample size, as well as the detailed and audited data capture on all infections during extended follow-up. No previous comparison of these 2 graft sources for use in transplantation has such a rich and detailed infection database with which to examine infectious complications for this important question of PBSC or BM as the graft source for allogeneic hematopoietic cell transplantation.
In this large randomized study of allogeneic hematopoietic cell transplantation, we observed a cumulative incidence of bacterial infections that is higher among patients who received BM rather than PBSC grafts for transplantation. The cumulative incidence of infections was driven by bacterial infections occurring before Day 100. Since the median time to neutrophil engraftment was 5 days longer for BM recipients than for those randomly assigned to receive PBSC, it is not surprising to see many bacterial infections early after transplant. These bacterial infections were more common prior to engraftment and over the two years 
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Author Manuscript following transplantation, but speed of engraftment or graft failure alone did not wholly account for this finding. Bacterial bloodstream infections accounted for 30% of all infections, a finding similar to an earlier prospective study of T cell depletion to limit GVHD after unrelated donor hematopoietic cell transplantation [17] .
There are no data regarding pre-or peri-transplant prophylaxis agents used, especially relevant for quinolones with the 123 cases of Clostridium difficile infection during this time prior to use of toxin-based PCR assays. As a result, antibacterial prophylaxis is a baseline characteristic that probably modulates the events seen but cannot otherwise be assessed.
During the analysis of transplant-related endpoints for this study, recipients of PBSC grafts had a higher rate of chronic GVHD, so infections that occurred after Day 100 were of particular interest, especially viral and fungal infections. CMV infections were not more frequent using BM or PBSC, even in the setting of GVHD. This study is the first comparative, long-term follow-up trial with infection data and does not support late CMV disease as a common event. Our database was not structured to capture self-limited (i.e., untreated) CMV viremia. Our database did not capture recurrent, refractory, or resistant CMV.
The probability of developing a clinically important CMV infection was less than 30% in each arm, a rate consistent with other studies published in the last 10 years, and lower than studies published earlier [17, [24] [25] [26] . In our study, there were 61 CMV infection episodes on the BM arm and 57 infections for patients transplanted using PBSC. The infection density for CMV infections was 0.25 for BM and 0.24 for PBSC during the Day 0 to Day 100 interval, declining to 0.06 for BM and to 0.10 for PBSC during the Day 100 to Day 180 interval, and to 0.03 for BM and to 0.05 for PBSC during the Day 181 to Day 365 interval. Survival among patients who developed a CMV infection was 41% for the BM arm and 49% for the PBSC arm. Regardless of study arm, this overall improved rate of any CMV infection, in comparison to studies published over the last 20 years, likely reflects changes in CMV monitoring/preemptive schemas, anti-CMV prophylaxis, the stem cell product itself, and in conditioning regimens over time. The rapid turnaround time in the newest generation of CMV diagnostic testing, and the availability of oral antiviral agents (e.g., valganciclovir), may have contributed to the low and comparable rates of CMV between the study arms.
By 2 years after transplant, the cumulative incidence of Aspergillus infection was 4% in each study arm, much lower than previously reported rates of 10-15% [17, 27] . The 4% rate (20 cases) represents some form of culture and/or histopathologic documentation, so these are cases of proven or probable infection but not possible infection. This is the lowest estimate of invasive aspergillosis in any allogeneic hematopoietic stem cell transplant series. The low rates of invasive aspergillosis may be related to ascertainment bias. Centers participating in this Clinical Trials Network perform bronchoscopies with various levels of aggressiveness, and when a bronchoscopy is performed, may have variable testing for Aspergillus galactomannan using lavage fluid. Thus, there is an undercount of probable and proven invasive aspergillosis since many of these pneumonias end up being "possible" invasive fungal infections or merely are treated empirically as fungal infection; in fact, there 
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Diagnostic testing for fungal infections was in a state of evolution during the years that this study was conducted. While the improvement in cumulative incidence is likely related to advances in antifungal agents that can be successfully employed with less toxicity and with prophylactic intent over the last 15 years, there was still a nontrivial rate of invasive fungal infections for the patients on this study. The 2-year cumulative incidence of invasive fungal infections was 16% for BM patients and 18% for PBSC patients. This includes 7 cases of mucormycosis, a fungal organism that is not within the spectrum of activity of either voriconazole or echinocandins, as well as 25 cases of "other fungus", some of which were clinical cases of pulmonary nodules responsive to antifungal therapy.
This detailed review of prospectively reported infectious disease events speaks to the challenges to infection data completeness and accuracy, even in this prospective and carefully monitored randomized trial. Despite prospective reporting, the initial audit of 15% of the patients (583 infections for 78 patients) identified frequent minor errors among one or more of the different data points associated with each infection (date, organism, body site, clinical severity). While these disagreements were not entirely correct as originally entered, most of these disagreements were minor did not affect the final results.
Accuracy of infection reporting goes down markedly after Day 100, when most patients leave the transplant center. When the accumulated list of all the infections was compared to the primary source documents, 65 previously unreported infections were identified. More than half of these infections occurred after Day 100. Twenty-two infections occurred after engraftment but before Day 100, of which two thirds were bacterial often coagulase negative Staphylococcus and one third were viral often CMV. The follow-up site self-audit used for this study indicates the importance of data accuracy, and argues for this type of approach in future studies evaluating complex, multiple endpoint infectious disease data, even if prospectively collected.
The data coordinating center has submitted all study data from this clinical trial, including these infection data, to the National Heart, Lung, and Blood Institute (NHLBI) data repository, so that future users should be able to access the data from a public end.
There are several limitations to interpreting a complex infection database when collected from hospitals across the study. There are differences in diagnostic testing at the various sites, and incidence rates may be altered based on current testing strategies (particularly for respiratory viruses and fungal infections). Additionally, with the detailed and complete retrospective audit of the protocol prescribed monitoring of infections, it is unlikely that many major infections were unrecognized.
This study noted a tremendous burden of infection among transplanted patients. Fortunately, infection was an uncommon cause of death. The incidence and severity of infection is lower than historical cohorts. The greatest differences were seen in the pre-engraftment time period. We need ways to continue to drive down the burden of infection for all patients. Morbidity and mortality from infection following transplantation was frequent using either 
Author Manuscript graft source, with no observed differences in fungal or viral infection rates. Among those who died, few had infection reported as the primary cause of death although many infections occurred in the final month of life. The higher observed risks of bacterial infections using BM grafts may suggest either augmented prophylaxis or heightened surveillance after these transplants.
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